AP734A - Method of treating a human with nervous insult with cyclosporin. - Google Patents

Method of treating a human with nervous insult with cyclosporin. Download PDF

Info

Publication number
AP734A
AP734A APAP/P/1997/001049A AP9701049A AP734A AP 734 A AP734 A AP 734A AP 9701049 A AP9701049 A AP 9701049A AP 734 A AP734 A AP 734A
Authority
AP
ARIPO
Prior art keywords
cyclosporins
blood
nervous
cyclosporin
insult
Prior art date
Application number
APAP/P/1997/001049A
Other languages
English (en)
Other versions
AP9701049A0 (en
Inventor
Eskil Elmer
Hiroyuki Uchino
Marcus Keep
Merab Kokaia
Original Assignee
Eskil Elmer
Hiroyuki Uchino
Marcus Keep
Merab Kokaia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eskil Elmer, Hiroyuki Uchino, Marcus Keep, Merab Kokaia filed Critical Eskil Elmer
Publication of AP9701049A0 publication Critical patent/AP9701049A0/xx
Application granted granted Critical
Publication of AP734A publication Critical patent/AP734A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/1997/001049A 1995-01-20 1996-01-18 Method of treating a human with nervous insult with cyclosporin. AP734A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9500209A SE520730C2 (sv) 1995-01-20 1995-01-20 Behandling av hjärnischemi och hjärnskador med ett neuroprotektivt läkemedel
PCT/SE1996/000036 WO1996022104A1 (fr) 1995-01-20 1996-01-18 Traitement de l'ischemie cerebrale et de degats cerebraux a l'aide d'un agent neuroprotecteur

Publications (2)

Publication Number Publication Date
AP9701049A0 AP9701049A0 (en) 1997-10-31
AP734A true AP734A (en) 1999-02-15

Family

ID=20396911

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001049A AP734A (en) 1995-01-20 1996-01-18 Method of treating a human with nervous insult with cyclosporin.

Country Status (18)

Country Link
US (1) US5972924A (fr)
EP (1) EP0813420B1 (fr)
JP (1) JP3643380B2 (fr)
CN (1) CN1123359C (fr)
AP (1) AP734A (fr)
AT (1) ATE218360T1 (fr)
AU (1) AU712974B2 (fr)
CA (1) CA2210241C (fr)
CZ (1) CZ291233B6 (fr)
DE (1) DE69621603T2 (fr)
DK (1) DK0813420T3 (fr)
ES (1) ES2176432T3 (fr)
MX (1) MX9706362A (fr)
NZ (1) NZ300699A (fr)
PT (1) PT813420E (fr)
RU (1) RU2194527C2 (fr)
SE (1) SE520730C2 (fr)
WO (1) WO1996022104A1 (fr)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19711795C2 (de) * 1997-03-21 2001-03-08 Apogepha Arzneimittel Gmbh Verwendung von Cyclosporin für die Behandlung von Myokardinfarkten und deren Folgen
US6844315B2 (en) 1998-05-20 2005-01-18 Erasmus Universiteit Rotterdam Immunoregulator
US20030220258A1 (en) 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US8680059B2 (en) * 1998-05-20 2014-03-25 Biotempt B.V. Oligopeptide acetate and formulations thereof
US20050227925A1 (en) * 2004-04-08 2005-10-13 Robbert Benner Compositions capable of reducing elevated blood urea concentration
US20040202645A1 (en) * 2003-04-08 2004-10-14 Khan Nisar Ahmed Administration of gene-regulatory peptides
US6921751B1 (en) * 1998-05-20 2005-07-26 Erasmus Universiteit Rotterdam Immunoregulator
EP1138692A1 (fr) 2000-03-29 2001-10-04 Erasmus Universiteit Rotterdam Fragments de gonadotrophine chorionique humaine comme immunorégulateurs
AP1040A (en) * 1998-09-17 2002-01-30 Panacea Biotec Ltd A novel composition containing cyclosporin.
IL142120A0 (en) * 1998-09-23 2002-03-10 Neuroimmunophilins for selective neuronal radioprotection
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
WO2000060943A1 (fr) * 1999-04-13 2000-10-19 North Shore-Long Island Jewish Research Institute Prevention de lesions cerebrales liees a des accidents vasculaires cerebraux
CA2383086A1 (fr) 1999-09-08 2001-03-15 Joseph P. Steiner Composes non-peptidiques de liaison cyclophiline et leur utilisation
DE19961733A1 (de) * 1999-12-21 2001-06-28 Ciclomulsion Ag Cyclosporin(e) enthaltende hypertone pharmazeutische Zubereitung zur Anwendung bei neurologischen Erkrankungen und als Neuroprotektivum sowie Verfahren zu ihrer Herstellung
KR20010069066A (ko) * 2000-01-12 2001-07-23 이종원 저산소 농도하에서 생존이 가능하도록 하는 동물세포의배양방법
US7358330B2 (en) 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
WO2001076517A2 (fr) * 2000-04-07 2001-10-18 The General Hospital Corporation D/B/A Massachusetts General Hospital Procedes et appareils utilises pour une affection thermique
EP1326562A1 (fr) 2000-10-05 2003-07-16 Seacoast Technologies, Inc. Dispositif expansible destine a une therapie thermique
US6656971B2 (en) 2001-01-25 2003-12-02 Guilford Pharmaceuticals Inc. Trisubstituted carbocyclic cyclophilin binding compounds and their use
US6936589B2 (en) * 2001-09-28 2005-08-30 Albert T. Naito Parenteral delivery systems
ES2326040T3 (es) 2001-10-19 2009-09-29 Isotechnika Inc. Sintesis de analogos de ciclosporina.
US20040013661A1 (en) * 2001-12-21 2004-01-22 Gert Wensvoort Stratification
US7560433B2 (en) 2001-12-21 2009-07-14 Biotempt B.V. Treatment of multiple sclerosis (MS)
US20030220261A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Treatment of iatrogenic disease
US20080242837A1 (en) * 2001-12-21 2008-10-02 Khan Nisar A Peptide compositions
US20030220257A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of trauma
US20030220260A1 (en) * 2001-12-21 2003-11-27 Khan Nisar Ahmed Peptide compositions
US7501391B2 (en) * 2001-12-21 2009-03-10 Biotempt B.V. Treatment of transplant survival
US20080318871A1 (en) * 2001-12-21 2008-12-25 Khan Nisar A Treatment of neurological disorders
US20030224995A1 (en) * 2001-12-21 2003-12-04 Khan Nisar Ahmed Treatment of burns
US7786084B2 (en) * 2001-12-21 2010-08-31 Biotempt B.V. Treatment of burns
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
US8420602B2 (en) * 2004-09-14 2013-04-16 Landon C. G. Miller Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders
US7074775B2 (en) * 2004-09-14 2006-07-11 Miller Landon C G Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders
JP4846799B2 (ja) * 2005-07-05 2011-12-28 バイオテンプト ベー．フェー． 腫瘍の治療
EP1864692A1 (fr) 2006-06-07 2007-12-12 Biotempt B.V. Utilisation de peptides pour la protection contre les radiolésions
KR101494675B1 (ko) * 2006-08-23 2015-02-23 더 유니버시티 오브 몬타나 신경 세포 손상을 감소시키는 방법
AU2008215193B2 (en) * 2007-02-12 2014-01-16 Biotempt B.V. Treatment of trauma hemorrhage with short oligopeptides
WO2011116007A1 (fr) * 2010-03-15 2011-09-22 Stealth Peptides International, Inc. Thérapies de combinaison utilisant de la cyclosporine et des peptides cationiques aromatiques
RU2475233C2 (ru) * 2010-12-01 2013-02-20 Учреждение Российской академии наук Институт кристаллографии им. А.В. Шубникова РАН Фармакологическая композиция, предназначенная для интраназального введения с целью доставки в мозг фармакологически активного компонента, и способ ее получения
RU2630690C9 (ru) 2010-12-15 2017-12-28 КонтраВир Фармасьютикалз, Инк. МОЛЕКУЛЫ АНАЛОГОВ ЦИКЛОСПОРИНА, МОДИФИЦИРОВАННЫЕ ПО 1 и 3 АМИНОКИСЛОТЕ
CN102784102A (zh) * 2012-08-28 2012-11-21 赵继红 一种河豚毒素口服液态制剂及其制备方法
US10123969B2 (en) 2015-10-15 2018-11-13 Wisconsin Alumni Research Foundation Osmotic enhancement of drug/therapeutic delivery to the brain following infusion or injection into the cerebrospinal fluid
WO2019232227A1 (fr) * 2018-05-30 2019-12-05 Zap Surgical Systems, Inc. Neuromodlation radiochirurgicale proche de structures critiques
US12036193B2 (en) 2019-09-15 2024-07-16 Celagenex Research (India) Pvt. Ltd. Synergistic bioactive compositions for treating neurological disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) * 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ACTA NEUROCHIRURGICA, Vol. 112, 1991, M. RYBA et al., "Cyclosporine A Prevents Neurological Deterioration of Patients with SAH - A Preliminary Report", 25-27. *
NEUROLOGY, NEUROSURGERY AND PSYCHIATRY, Vol. 53, 1990, S. J. HODGKINSON et al., "Cyclosporin A in the Treatment of Chronic Demelinating Polygradiculoneuropathy" pp.327-330 *

Also Published As

Publication number Publication date
EP0813420B1 (fr) 2002-06-05
SE9500209D0 (sv) 1995-01-20
CN1123359C (zh) 2003-10-08
WO1996022104A1 (fr) 1996-07-25
AU712974B2 (en) 1999-11-18
MX9706362A (es) 1998-07-31
JP3643380B2 (ja) 2005-04-27
ES2176432T3 (es) 2002-12-01
DE69621603T2 (de) 2002-09-19
DK0813420T3 (da) 2002-09-30
CZ233697A3 (cs) 1998-07-15
ATE218360T1 (de) 2002-06-15
CZ291233B6 (cs) 2003-01-15
AU4592496A (en) 1996-08-07
JPH11504617A (ja) 1999-04-27
SE520730C2 (sv) 2003-08-19
DE69621603D1 (de) 2002-07-11
NZ300699A (en) 1998-05-27
PT813420E (pt) 2002-10-31
SE9500209L (sv) 1996-07-21
US5972924A (en) 1999-10-26
CA2210241C (fr) 2000-06-20
RU2194527C2 (ru) 2002-12-20
CN1178469A (zh) 1998-04-08
AP9701049A0 (en) 1997-10-31
CA2210241A1 (fr) 1996-07-25
EP0813420A1 (fr) 1997-12-29

Similar Documents

Publication Publication Date Title
AP734A (en) Method of treating a human with nervous insult with cyclosporin.
Nagano et al. Beneficial effects of intrathecal IGF-1 administration in patients with amyotrophic lateral sclerosis
US6796966B2 (en) Apparatus, and kits for preventing of alleviating vasoconstriction or vasospasm in a mammal
US6358536B1 (en) Nitric oxide donor compositions, methods, apparatus, and kits for preventing or alleviating vasoconstriction or vasospasm in a mammal
CA2687505C (fr) Compositions pharmaceutiques et procedes permettant d'amplifier le ciblage de composes therapeutiques sur le systeme nerveux central
EP2384198A2 (fr) Compositions pharmaceutiques et procédés de traitement de lésions neurologiques
WO2004080476A1 (fr) Utilisation de secretine dans le traitement de la schizophrenie
US20040147433A1 (en) Neuroimmunophilins for selective neuronal radioprotection
AU766095B2 (en) Neuroimmunophilins for selective neuronal radioprotection
US7446093B1 (en) Cerebrospinal and vascular pharmaceutical composition and process for preparing the same
RU2212890C2 (ru) Раствор для инфузий бравинтон для улучшения мозгового кровообращения
MXPA01003029A (en) Neuroimmunophilins for selective neuronal radioprotection
CN105963287A (zh) 复方组合物及其医药用途
CN115957220A (zh) 硝酮嗪在制备治疗缺血性脑卒中药物中的应用
CN116585447A (zh) 脑卒中联合用药物及其应用
CN114129516A (zh) 异榄香脂素类化合物乳剂及其制备方法与应用
CN108853483A (zh) 经修饰的胸腺素β4在治疗脑缺血再灌注损伤方面的用途
Abrahám Cerebral Ischemia Reperfusion-lnduced Vasogenic Brain Edema Formation in Rats: Effect of an Intracellular Histamine Receptor